Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
The priming of tumor-antigen-specific T cells is critical for the initiation of successful anti-tumor immune responses, yet the fate of such cells during tumor progression is unknown. Naive CD4(+) T cells specific for an antigen expressed by tumor cells were transferred into tumor-bearing mice. Transient clonal expansion occurred early after transfer, accompanied by phenotypic changes associated with antigen recognition. Nevertheless, these cells had a diminished response to peptide antigen in vitro and were unable to be primed in vivo. The development of antigen-specific T cell anergy is an early event in the tumor-bearing host, and it suggests that tolerance to tumor antigens may impose a significant barrier to therapeutic vaccination.
Staveley-O'Carroll
K
K
Departments of Surgery and Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Sotomayor
E
E
Montgomery
J
J
Borrello
I
I
Hwang
L
L
Fein
S
S
Pardoll
D
D
Levitsky
H
H
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D000956:Antigens, Viral / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use; D017635:Clonal Anergy / Q000276:immunology*; D018450:Disease Progression; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology; D016219:Immunotherapy, Adoptive; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D014407:Tumor Cells, Cultured; D014616:Vaccinia virus / Q000276:immunology
D000951:Antigens, Neoplasm; D000956:Antigens, Viral; D019496:Cancer Vaccines; D019267:Hemagglutinin Glycoproteins, Influenza Virus